Cargando…

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site

Detalles Bibliográficos
Autores principales:	McLellan, JS, Gorman, J, Bonsignori, M, Hwang, K, Liao, H, Rerks-Ngarm, S, Nitayaphan, S, Michael, NL, Kim, JH, Haynes, BF, Kwong, PD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441966/ http://dx.doi.org/10.1186/1742-4690-9-S2-P107

Ejemplares similares

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee()
por: Nicely, Nathan I., et al.
Publicado: (2015)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
por: Fischinger, Stephanie, et al.
Publicado: (2020)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
por: Choi, Ickwon, et al.
Publicado: (2015)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand
por: Pitisuttithum, Punnee, et al.
Publicado: (2015)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144
por: Perez, Lautaro G., et al.
Publicado: (2017)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
por: Karnasuta, Chitraporn, et al.
Publicado: (2017)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
por: Hertz, T, et al.
Publicado: (2012)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
por: Bonsignori, M, et al.
Publicado: (2012)

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
por: Gottardo, Raphael, et al.
Publicado: (2013)

RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2020)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
por: Karasavvas, N, et al.
Publicado: (2012)

Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial
por: Edlefsen, Paul T., et al.
Publicado: (2015)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses
por: Mdluli, Thembi, et al.
Publicado: (2021)

RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection
por: Lewitus, Eric, et al.
Publicado: (2021)

Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial
por: Zolla-Pazner, Susan, et al.
Publicado: (2013)

Molecular epidemiology of the protective RV144 V2 loop epitope
por: Cardozo, T
Publicado: (2012)

Recombinant Env proteins that bind the quaternary-specific, V1/V2-directed PGT antibodies
por: Gorman, J, et al.
Publicado: (2012)

CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants
por: Dommaraju, Kalpana, et al.
Publicado: (2014)

HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis
por: Wills, Saintedym, et al.
Publicado: (2018)

Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent
por: Zhang, Meng, et al.
Publicado: (2022)

Fcgbp – A Potential Viral Trap in RV144
por: Schwartz, Jacquelyn L
Publicado: (2014)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
por: Akapirat, Siriwat, et al.
Publicado: (2018)

Detection of antibodies to the α4β7 integrin binding site on HIV-1 gp120 V2 loop using a novel cell adhesion assay
por: Rao, M, et al.
Publicado: (2012)

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability
por: Shubin, Zhanna, et al.
Publicado: (2023)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
por: Pitisuttithum, P, et al.
Publicado: (2009)

OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
por: Kim, JH, et al.
Publicado: (2009)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes
por: Pollara, J, et al.
Publicado: (2012)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay
por: Bonsignori, M, et al.
Publicado: (2009)

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
por: Leier, Hans C., et al.
Publicado: (2021)

Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees
por: Wu, Minghui, et al.
Publicado: (2022)

Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees
por: Garziano, Micaela, et al.
Publicado: (2022)

Interactions between Severe Allergy and Anxiety in Anti-SARS-CoV-2 Vaccinees
por: Asperti, Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ppf6ucuerfbmgdm7q7l14ftobm